Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence. However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis. Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer. Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to reeducate stromal cells within the TME to have anti-tumorigenic effects.
Bidirectional communication between cells and their microenvironment is critical for both normal tissue homeostasis and tumor growth. In particular, interactions between tumor cells and the associated stroma represent a powerful relationship that influences disease initiation and progression and patient prognosis 1 . The link between chronic inflammation and tumorigenesis was first proposed by Rudolf Virchow in 1863 after the observation that infiltrating leukocytes are a hallmark of tumors 2 . Since then, a plethora of studies have contributed to the characterization of the TME, further complicating the already challenging task of understanding and treating cancer. Whereas cancer was previously viewed as a heterogeneous disease involving aberrant mutations in tumor cells, it is now evident that tumors are also diverse by nature of their microenvironmental composition and their stromal cell proportions or activation states 3, 4 . In response to evolving environmental conditions and oncogenic signals from growing tumors, the TME continually changes over the course of cancer progression, underscoring the need to consider the influences of the TME on metastasis as a dynamic process and understand how tumor cells drive the construction of their own niche.
Here we discuss current research that demonstrates a crucial role for different stromal compartments during cancer development and metastasis, as well as recent therapeutic strategies to target the tumorassociated stroma to prevent or regress disease. In light of the breadth and complexity of each step in the invasion-metastasis cascade and the abundance of microenvironmental influences that have a role during each phase of cancer progression, we chose to focus our discussion on specific aspects of the TME during primary tumor growth, survival in the periphery and secondary outgrowth. We also discuss evidence supporting the extent of interconnectedness within cancers, whereby stromal cells signal not only back and forth to tumor cells but also to each other, representing the inherent complexity of the TME. For further discussion on topics not covered in extensive detail here, we direct readers to other recent reviews [5] [6] [7] [8] [9] [10] [11] .
Clinical associations between inflammation and tumor incidence One of the most direct pieces of evidence that a deregulated microenvironment affects tumorigenesis is that tissues that are subject to chronic inflammation generally exhibit high cancer incidence 12 . For instance, hepatocellular carcinoma is the leading cause of death in patients with liver cirrhosis of various etiologies. In a retrospective cohort study of 417 cancer-free patients with cirrhosis, 27% developed liver cancer over ~12 years 13 . In another large study of 19,486 patients with inflammatory bowel disease, 2,841 of which exhibited long-term colitis, the increased risk of colorectal cancer in these two groups was 2.2-and 7.0-fold, respectively 14 . The onset of tumorigenesis in these tumor types is supported by an unresolved inflammatory response, whereby various stromal cell types accumulate, become activated, their normal function to maintain homeostasis becomes maladaptive, and a pro-tumorigenic niche ensues 1, 15 . Interestingly, a recent meta-analysis found that in ~15% of cancers, tumor initiation can be directly attributed to infection by different etiological agents, including viruses, bacteria and parasites 16 . Moreover, these cancers are associated with chronic inflammation, supporting the growing connection between infection, inflammation and cancer 12 .
However, it is also critical to note that impaired immune responses can correlate with high cancer incidence. In an analysis of 25,914 female immunosuppressed organ transplant recipients, the observed tumor incidence was higher than predicted for multiple cancers, including lung, gastrointestinal, reproductive and skin cancers 17 . In contrast, breast cancer incidence decreased in this cohort, illustrating the paradoxical nature of immune responses. Furthermore, an analysis of 122,993 individuals evolves to accommodate the growing tumor ( Fig. 1 and Box 1) 1, 27, 28 . In the next section, we discuss how the tumor-associated stroma at primary sites is hijacked to support tumor growth, with a focus on the role of macrophages, immune suppressor cells, fibroblasts, the vasculature and various other components of a tumor-supportive TME.
Macrophage plasticity contributes to tumor growth. Tumor-associated macrophages (TAMs) are important regulators of tumorigenesis that are either tissue resident or derived from peripheral reservoirs such as the bone marrow (BM) and spleen. Although macrophages are classically regarded as critical effector cells during immune defense, numerous studies have demonstrated a clear role for TAMs in supporting multiple aspects of tumor progression 29 (Fig. 1) . Perhaps most notable is their role at the leading edge of tumors, where they drive invasive cellular phenotypes 30 . Indeed, studies in breast cancer and glioma have demonstrated that TAMs facilitate tumor cell invasion through a paracrine signaling loop that involves tumor-derived colony-stimulating factor 1 (CSF-1) and macrophage-derived epidermal growth factor (EGF) [30] [31] [32] . Beyond the leading edge, TAMs are a major source of proteases, such as cysteine cathepsins, which support tumor progression and therapeutic resistance in multiple cancer types [33] [34] [35] .
One explanation for the disparate roles of macrophages during normal tissue homeostasis and tumorigenesis lies in their phenotype. Macrophages are functionally plastic and can alter their polarization state to accommodate different physiological conditions ( Table 1) . At the extremes of their phenotypic continuum 36 , macrophages range from M1 to M2 polarization states: 'classically activated' M1 macrophages produce with AIDS revealed elevated incidence of not only AIDS-related cancers (for example, Kaposi's sarcoma) but also non-AIDS-related cancers (for example, cancers of the tongue, skin, lung or central nervous system and multiple myeloma) 18 . Similar retrospective analyses 19, 20 have indicated that adequate immune function may be protective against certain cancers, contrasting with evidence that supports pro-tumorigenic functions for inflammation 12 . This dichotomy underscores the challenges in understanding and therapeutically targeting context-dependent, opposing functions of immune cells in cancer.
Amid this complexity, therapeutic opportunity lies in the pliancy of the tumor stroma, which imparts strong influences on disease progression. For example, whereas tumor-associated macrophages exhibit pro-tumorigenic effects in response to stimulation or education by cytokines (for example, interleukin-4 (IL-4) or transforming growth factor-b (TGF-b), among others) in many solid tumors, they can also be reprogrammed by various pharmacological agents to exhibit anti-tumor behavior [21] [22] [23] [24] [25] [26] . We can potentially take advantage of this plasticity by reprogramming or re-educating cells in the TME to treat cancer rather than simply targeting stromal cells for ablation.
Primary growth begins: tissue homeostasis undone
In addition to the clinical association studies discussed above, it is evident that tumorigenesis is indeed modulated by aberrant immune responses and altered homeostasis. In cancer, the coordinated intercellular interactions that are present in normal adult tissues are disrupted as the tumor acquires the capacity to chronically circumvent normalizing cues from the microenvironment, and in turn, the microenvironment Figure 1 Multiple stromal cell types converge to support a tumorigenic primary niche. After circumventing cell-intrinsic mechanisms of apoptosis, tumor cells are subject to elimination pressures by the immune system. Tumor cell-specific antigens have a role during this process, which are recognized by cytotoxic immune cells, leading to their destruction. Fibroblasts and macrophages within the TME also contribute to a growth-suppressive state; however, these cells may later become educated by the tumor to acquire pro-tumorigenic functions. For instance, TAMs support diverse phenotypes within the primary tumor, including growth, angiogenesis and invasion, by secreting a plethora of pro-tumorigenic proteases, cytokines and growth factors (for example, EGF, which participates in a paracrine signaling loop through tumor-secreted CSF-1). As tumors grow, immune-suppressor cells, including MDSCs and T reg cells are mobilized into the circulation in response to activated cytokine axes that are induced by tumorigenesis (for example, TGF-b and CXCL5-CXCR2). MDSCs and T reg cells infiltrate the growing tumor to disrupt immune surveillance through multiple mechanisms, including, but not limited to, disruption of antigen presentation by DCs, inhibition of T and B cell proliferation and activation or inhibition of NK cell cytotoxicity. CAFs, which become activated by tumor-derived factors (for example, TGF-b, FGF or PDGF, among others), secrete ECM proteins and basement membrane components, regulate differentiation, modulate immune responses and contribute to deregulated homeostasis. CAFs are also a key source of VEGF, which supports angiogenesis during tumor growth. In addition to cellular contributions, several extracellular properties contribute to tumor progression, including low oxygen tension, high interstitial fluid pressure and changes in specific components of the ECM. EndMT, endothelial-to-mesenchymal transition; Ag, antigen.
and the subsequent acquisition of an invasive phenotype 37 , suggesting that the initial hypoxic response in growing tumors may include a switch in macrophage polarization 38 . Reversion of TAMs back to an M1 phenotype has also been reported. For example, TAM-specific inactivation of IKK-b, which disrupts nuclear factor kB (NF-kB) signaling, resulted in an M2-to-M1 switch, recruitment of natural killer (NK) cells and subsequent tumor regression in an ovarian cancer model 24 . Other studies using Lewis lung carcinoma (LLC) cells have implicated tumor necrosis factor-a (TNFa) in regulating this conversion, downstream of Toll-like receptor 3 (TLR3) and Toll-IL-1 receptor domain-containing adaptor molecule 1 (TICAM-1) 39 . Another report on LLC found that miR-155 overexpression in TAMs induced repolarization toward an anti-tumoral M1 state 40 . We recently showed that macrophage depolarization from an M2 phenotype by CSF-1R inhibition was associated with a robust type I proinflammatory cytokines, participate in antigen presentation and have an anti-tumorigenic role 21 . Conversely, 'alternatively activated' M2 macrophages produce type II cytokines, promote anti-inflammatory responses and have pro-tumorigenic functions 21 . However, it should be noted that although this classification is useful, it is somewhat oversimplified, as it does not fully represent the complexity of macrophage activation, which is often fine tuned in response to different tissue microenvironments 36 . Currently, we do not fully understand how macrophages initially switch from tumor suppressing to tumor promoting at the onset of disease. It has been suggested that environmental conditions such as tumor hypoxia may mediate this transition. Indeed, TAMs accumulate in regions of hypoxia in growing tumors 37 , and their recruitment is mediated by an upregulation of macrophage chemoattractants, including endothelin-2 and vascular endothelial growth factor (VEGF). Of note, TAM accumulation in these regions correlates with angiogenesis Regulatory T (T reg ) cells are another TME cell type that has diverse immune modulatory functions in cancer 22, 51 . Under normal physiological conditions, T reg cells regulate the expansion and activation of T and B cells and have a critical role in maintaining the homeostasis of innate cytotoxic lymphocytes 52 . Given their complex regulatory roles in response to different environmental stimuli, it is not surprising that T reg cells have diverse effects on tumorigenesis. In some tumor types, including breast cancer and hepatocellular carcinoma, increased numbers of T reg cells correlate with reduced overall survival 53, 54 , whereas in other types, such as colorectal cancer, T reg cells are associated with improved survival 55 . Similar to MDSCs, T reg cells suppress tumor-associated antigen presentation and also interfere with cytotoxic T cell function by inhibiting cytolytic granule release 56 .
The mechanisms underlying divergent T reg cell functions in cancer remain elusive; it is not clear whether T reg cells exhibit context-dependent functionality or whether they encompass multiple subpopulations with distinct functions that are not differentiated using conventional markers 57 . Indeed, tumor-associated T reg cell phenotypes are heterogeneous 58 , suggesting that they likely accumulate by various mechanisms such as peripheral recruitment, proliferation of cells in the TME or differentiation of progenitors in response to tumor-secreted factors. As such, targeting T reg cells using antibodies to CD25 or other pharmacological approaches 56, 59 will likely be most beneficial in the context of improving immunotherapy responses in cancer, similarly to MDSCs 44 .
Cancer-associated fibroblasts elicit pro-tumorigenic functions. Fibroblasts are a predominant, multifunctional cell type in connective tissue, depositing extracellular matrix (ECM) and basement membrane components, regulating differentiation events in associated epithelial cells, modulating immune responses and mediating homeostasis 60, 61 . In the TME, cancer-associated fibroblasts (CAFs) are present in aberrantly high numbers and are distinct from normal fibroblasts. For example, normal prostate epithelial cells give rise to intraepithelial neoplasia in mice when co-injected with CAFs but not when co-injected with normal fibroblasts 62 . Similarly, in breast cancer, CAFs confer a mesenchymal-like phenotype and enhance the metastasis of both premalignant and malignant mammary epithelial cells, whereas normal fibroblasts promote an epithelial-like phenotype and suppress metastasis 63 . These effects regression of established high-grade gliomas 25 . Together these studies highlight a potential therapeutic opportunity in which re-educating TME-resident macrophages might have beneficial anti-tumorigenic effects on disease.
Immune suppression by myeloid-derived suppressor cells and regulatory T cells. A critical step in the malignant progression of incipient tumors is evasion and suppression of the host immune system 6, 41 ( Fig. 1) . This step can be achieved through inhibition of various effector immune cells or by stimulation of immunosuppressive cells ( Table 1) . One of the most prevalent mechanisms of immune evasion in patients is through the suppressive activity of myeloid-derived suppressor cells (MDSCs) 42 , which arises as a consequence of the aberrant myelopoiesis that occurs in cancer. MDSCs are functionally defined as immunosuppressive, immature myeloid cells 43 that maintain normal tissue homeostasis in response to various systemic insults, including infection and traumatic stress. MDSCs are mobilized during tumorigenesis and infiltrate developing tumors, where they promote tumor vascularization 43 and disrupt major mechanisms of immunosurveillance, including antigen presentation by dendritic cells (DCs) 44 , T cell activation [44] [45] [46] , M1 macrophage polarization 47 and inhibition of NK cell cytotoxicity 48 . The notion that MDSCs promote tumor progression has been demonstrated in several animal models, in which depletion with various neutralizing antibodies markedly reduced metastasis (reviewed in ref. 43) , and is supported by the observation that patients with cancer exhibit elevated numbers of peripheral MDSCs, which positively correlates with advanced disease and therapeutic inefficacy 42, 49 .
Designing therapies that aim to re-educate the immunosuppressive activity of MDSCs is an attractive approach, given that they are composed of mixed subpopulations of cells with varying maturities and plasticities and can differentiate into multiple cell types. It has been shown in animal models that monocytic MDSCs can be reprogrammed to adopt an antitumorigenic phenotype in response to mimicking bacterial stimulation of the immune system 50 . This transition is accompanied by an increase in proinflammatory T helper type 1 (T H 1) cytokines, a reduction in T cellsuppressive factors (for example, arginase-1 or nitric oxide) and differentiation of MDSCs into M1-like macrophages 50 . These findings suggest that immunomodulatory therapies developed for subverting responses to infection may also be relevant in the context of cancer.
BOX 1 Emerging stromal cell types that influence tumorigenesis
There are several stromal cell types that are emerging as having robust influences on cancer. For instance, adipocytes and their progenitors, and the apoptotic crown-like structures that they form with phagocytic macrophages in obese individuals, contribute to tumor progression across a variety of obesity-associated cancers [184] [185] [186] [187] . Moreover, adipose stromal cells can be recruited to growing tumors, where they differentiate into pericytes and incorporate into vessel walls 188 , demonstrating that similarly to tumor cells, stromal cells in the TME can exhibit cellular plasticity that contributes to tumorigenesis. Nonclassical stem-promoting functions of nerves in both the BM and local environment 189, 190 may also mediate cancer malignancy, given the association between perineural invasion and neurogenesis in several tumor types, including gastrointestinal, pancreatic and prostate cancers [191] [192] [193] [194] . Therapies that mitigate nerve impulses, such as botulinum toxin (Botox), may therefore have beneficial effects in some patients. In addition, the gut microbiome and associated inflammation are now accepted as major influences in the outcome of colorectal cancers. Indeed, the US National Institutes of Health has initiated an effort to fully characterize the human microbiome in various anatomical sites, including the gut, in health and disease. Treatment with antiinflammatory (such as aspirin) or antimicrobial agents mitigates colorectal cancer tumorigenesis and extends patient survival 195 . Rather than completely disrupting the gut microbiome, it is possible that these agents are capable of augmenting the microbiome composition, thus creating an unfavorable environment for tumor growth. Re-education of the TME, in this case through alterations in cellular proportions, may again have favorable consequences for cancer. Interestingly, whether reintroduction of proinflammatory microbiota (i.e., those that existed before treatment) allows tumorigenesis to resume has not been established and might suggest that long-term management of the gut microbiota could be critical to patient outcome. Given the emergence of nonclassical stromal cell types in cancer, more creative combination tumor therapies may have an untapped benefit in managing disease progression. Furthermore, the TME should not be viewed as simply a local result of tumor burden; the systemic microenvironment is also capable of modulating disease progression and ought to be considered for therapeutic intervention.
despite initial resistance. Angiogenesis is now accepted as a hallmark of cancer 4 in response to a growing need for oxygen and nutrients from the bloodstream, without which tumors would succumb to dormancy. Tumor vascularization requires the co-operation of multiple TME cell types, including vascular endothelial cells (which form tight adhesions to ensure vessel integrity), pericytes (which provide vessel coverage and dictate vessel maturity) and BM-derived precursor cells, whose orchestration is often regulated by hypoxia ( Fig. 1 ) 5, 76, 77 .
In addition to the cell types comprising the actual vessels, accessory cells, including TAMs, mesenchymal stem cells (MSCs) and CAFs, also contribute to tumor vascularization by releasing a plethora of proangiogenic signals into the TME. The dichotomous role of MSCs in modulating angiogenesis is particularly intriguing; whereas co-injection of MSCs and colon cancer cells into mice induced a significant increase in tumor incidence and microvascular density 78 , when MSCs were coinjected with glioma cells, vascularization was prevented as compared to glioma cells that were injected with normal astrocytes 79 . These inhibitory effects were mediated by a reduction of endothelial progenitor cell (EPC) recruitment to gliomas and a decrease in key signaling molecules that are involved in gliomagenesis, such as PDGF-BB 79 . Conversely, in patients with advanced highly vascularized breast cancer, there is substantial mobilization of MSCs into the circulation, which is associated with chemoresistance 80 . These results, among many others 81 , demonstrate that the functions of MSCs in tumor progression are also highly contextual and are likely dependent on the stromal composition or an impending need for oxygenation.
Lymphangiogenesis is another mode of vascularization in tumors, and lymphatic vessels represent an alternate route for cancer cell dissemination 82 . Activated macrophages produce VEGF-C and VEGF-D, which correlate with peritumoral inflammation and lymphangiogenesis in human cervical cancer 83 . Moreover, myeloid cell populations can have critical influences on lymphatic endothelial cells (LECs) by not only modulating their signal transduction but also transdifferentiating into functional LEC-like cells. In one retrospective study, tissues were analyzed from patients who received sex-mismatched renal transplants who exhibited transplant rejection, lymphatic activation and inflammation and showed incorporation of recipient LEC progenitors into the lymphatic vasculature in transplanted tissue 84 . Similarly, in mouse cancer models, myeloid cell incorporation and transdifferentiation into LECs have been reported, as mediated by VEGF-C and heparanase, among other factors 85, 86 . Interestingly, the ability of peripheral LEC progenitors to incorporate into newly formed lymphatic vessels is reminiscent of the de novo vascularization of tumors by EPC incorporation into vessel walls and of early embryonic vasculogenesis, highlighting the parallels between these physiological and pathological processes.
Cancer cell dissemination and survival in the periphery Once the primary tumor acquires the capacity to evade host immune defenses and cancer cells enter the circulation, metastatic dissemination is underway. Prior to this event, the primary tumor may have already primed premetastatic sites to be receptive to incoming tumor cells 87 . Furthermore, recruited cell types that were once destined to destroy the primary tumor have now been hijacked to facilitate its journey through the body (Fig. 2) . In this section we discuss how the TME supports cancer cells in leaving the primary tumor site and seeding successfully in secondary organs.
Stromal influences on phenotypic switching. One of the initiating steps of primary tumor invasion is the EMT, during which tumor cells lose epithelial markers and gain mesenchymal traits that confer stem-like properties and a migratory phenotype 88 (Fig. 2) . This program recapitulates highlight the complexity of fibroblast functionality in cancer (Fig. 1) and indicate that CAFs ought to be considered an entirely different cell type from normal fibroblasts, one with potent effects on tumorigenesis.
It is unclear from where CAFs arise during disease progression 64 . Some studies have suggested that they are generated from an endothelial-to-mesenchymal transition, whereby tumor-associated endothelial cells delaminate from blood vessels to generate mesenchymal cells with multipotent differentiation potential. Lineage-tracing experiments in mouse melanomas and pancreatic neuroendocrine tumors showed that CAFs in these tumors were of endothelial cell origin 65 . The epithelial-tomesenchymal transition (EMT) also promotes the generation of CAFs, whereby tumor cells of epithelial origin (for example, in breast and prostate cancers) dedifferentiate to generate a mesenchymal-like cell population that expresses CAF markers 66, 67 . EMT has also been linked to the generation of fibroblasts that participate in normal tissue homeostasis, for example, in response to chronic injury of renal epithelial cells 68 .
Once CAFs accumulate in the TME, they are activated by growth factors and cytokines that are present in the surrounding milieu. TGF-b, monocyte chemotactic protein (MCP1), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and secreted proteases have all been implicated in CAF activation 61, 64 . In a recent study, induction of the YAP transcription factor was required for the ability of CAFs to remodel the ECM to support tumorigenesis 69 . YAP induction in turn regulates multiple factors that modulate the cytoskeleton and matrix stiffness, which feed back to further enhance YAP production. After activation, CAFs provide a major source of secreted growth factors that support tumorigenesis, including VEGF, which induces vascular permeability and angiogenesis 70 . CAFs additionally produce proinflammatory factors that activate NF-kB signaling to promote tumorigenesis, and a proinflammatory CAF signature is already evident in preneoplastic lesions 71 . Interestingly, CAFs in the breast TME can select for bonespecific metastatic traits in primary tumor cells, in part because of a selective interaction between breast cancer cells with high Src activity and primary CAFs that secrete chemokine (C-X-C motif) ligand 12 (CXCL12) and insulin-like growth factor 1 (IGF1) 72 . This raises the intriguing possibility that heterotypic signaling in the primary TME enriches for metastatic cells that are primed to flourish in specific foreign microenvironments, providing further evidence for the interdependency of multiple cell types within the TME.
Extracellular cues influence tumor progression. Beyond the contributions of specific cell types to tumorigenesis, the ECM has a capacity to limit cancer initiation at early stages and drive disease progression toward malignancy at later stages. Indeed, the composition of the extracellular TME is a major predictor of clinical prognosis. In breast cancer, tumors can be stratified into four subclasses based strictly on ECM composition, which are predictive of patient outcome 73 . Tumors with high expression of protease inhibitors (for example, serpin family members) in their ECM are associated with good prognosis, whereas tumors with high expression of integrins and matrix metallopeptidases (MMPs) correlate with poor prognosis and risk of recurrence 73 . Different cell types in the TME supply distinct ECM proteins, which has been termed the 'matrisome' , as identified through proteomics strategies 74 . Interestingly, primary tumors of diverse metastatic potential differ in their composition of both tumor-and stroma-derived ECM components 74 . Together these results suggest that disrupting the extracellular environment that surrounds and infiltrates tumors may provide an additional level of therapeutic intervention.
The tumor vasculature is supported by the TME and maintains tumor growth. In 1971, Judah Folkman published a revolutionary article proposing that all tumors are angiogenesis dependent 75 , which initiated a paradigm shift throughout the cancer research community Given that many patients rebound after chemotherapy, supposedly because of an inability of chemotherapeutic agents to target 'stemlike' cell populations, an understanding of how stromal cell compartments contribute to the acquisition of a mesenchymal phenotype could inspire innovative combination therapies that target both rapidly dividing and tumor-initiating cell populations. Alternatively, taking advantage of stromal-mediated epithelialization may be advantageous in combination with chemotherapy, whereby reprogramming the premetastatic 'soil' may have multiple beneficial consequences for subverting metastasis.
Stromal cells lead the way at the invasive edge. The tumor margin is an important meeting place in the TME where recruited immune and stromal cells are highly active and interactive with the tumor (Fig. 2) . Immature myeloid cells accumulate in this region and prevent the differentiation of antigen-presenting DCs, thus supporting tumor immune evasion 44 . Macrophages are another major cell type at the invasive edge of tumors and are recruited by tumor-derived chemoattractants 30 . After their arrival, TAMs promote the invasion of tumor cells by supplying pro-migratory factors such as EGF, by regulating the production of fibrillar collagen to accelerate tumor motility and by promoting ECM proteolytic remodeling 34, 97, 98 . CAFs are similarly abundant at the tumor margin, where they release proinvasive factors for tumor cells; in many processes that are involved in mammalian development and adult tissue remodeling 89 , suggesting that the tumor-associated EMT is similarly an attempt to reorganize tissue and maintain homeostasis. At later stages of metastasis, however, secondary lesions often display an epithelial-like phenotype, suggesting that this mesenchymal-epithelial transition (MET) is important for metastatic outgrowth [90] [91] [92] . This notion underscores the importance of phenotypic switching, rather than the EMT per se, for successful metastasis and suggests that tumor cells may fluctuate along an epithelial-mesenchymal continuum in response to cues from different environments.
Indeed, several studies have demonstrated the importance of the stroma during phenotypic transition events in cancer, generally by supplying or inhibiting TGF-b 89 . For example, macrophage accumulation in teratocarcinomas causes EMT as a result of elevated TAM-derived levels of TGF-b 93 . The EMT can additionally be induced by platelet-tumor cell interactions through platelet-secreted TGF-b 94, 95 . In gastric carcinoma, the proportion of CD133 + tumor cells is regulated by paracrine TGF-b and WNT signaling with MSCs 96 . In breast cancer, BM-derived myeloid progenitors are recruited to the premetastatic lung 87 , where they induce the MET of tumor cells through downregulation of SMAD2 signaling (the canonical TGF-b pathway) and a switch to macrometastatic growth 90 . Debbie Maizels tive aggregates with tumor cells, which interferes with NK cell-mediated cytotoxicity by enhancing fibrin deposition and impeding immune cell recognition 94, 114 . These platelet-tumor cell clusters thereby provide an additional layer of immune evasion, which may contribute to disease progression. During the physiological response to vascular injury, platelets become activated by thrombin, allowing them to attach to the endothelium, and aggregate to form a fibrin clot. Reminiscent of their role during this process, platelets mediate attachment to the endothelium when tumor cells arrive at secondary organs. Integrins expressed on platelets interact with collagen that becomes exposed at stripped regions of the endothelium, causing platelet activation. Thus, endothelial cell retraction at the secondary site, induced by circulating tumor cells or tumor cell-associated leukocytes, may be an important component of the premetastatic niche that dictates where metastatic tumor cells will exit circulation 94, 115 . Indeed, a recent study found that platelets promote tumor cell extravasation through ATP-dependent activation of the endothelial P2Y 2 receptor, which opens the vessel barrier to enable metastatic seeding 116 . In light of the various contributions of platelets to cancer progression, it is not surprising that in patients, thrombocytosis (high platelet count) is associated with poor prognosis across multiple cancers, including breast cancer, glioblastoma multiforme and pancreatic cancer [117] [118] [119] .
Extravasation of tumor cells and secondary seeding is requisite for metastatic outgrowth. Primary tumors upregulate fibronectin expression by resident fibroblasts in secondary organs, which serves as a docking site for VEGFR1 + hematopoietic progenitor cell (HPC) clusters and the subsequent arrival of tumor cells 120 . Additional studies have demonstrated that during metastasis of breast cancer to the lung, VCAM-1-positive cancer cells associate with VLA-4 (also called integrin α4β1)-expressing macrophages 121 . This interaction activates phosphatidylinositol 3-kinase (PI3K)-AKT signaling in tumor cells, protecting them from caspase-induced apoptosis. Indeed, interruption of this interaction renders metastatic cells susceptible to apoptotic insult 121 . Interestingly, VCAM-1 also interacts with a different integrin partner, α4β1, in osteoclasts, contributing to bone metastasis 122 . Together, these findings suggest that disruption of adhesion signaling axes between stromal cells and tumor cells may serve to prevent metastatic colonization of multiple organs.
Metastatic colonization and organ tropism: establishing a secondary niche. Organ tropism, more classically known as the seedand-soil hypothesis, was first proposed by Stephen Paget in 1889, when he concluded that the distribution of metastases was not random but instead displayed clear organ preference. Paget's hypothesis later spawned the idea that before metastatic dissemination, primary tumors secrete factors that contribute to the development of a premetastatic niche, which is characterized by an abundance of BM-derived cell types, increased numbers of fibroblasts and secreted oncoproteins and cytokines that render the secondary environment receptive to tumor growth (Fig. 2) . In alignment with this concept, it has been shown that BM-derived VEGFR1 + cells colonize premetastatic sites before tumor cell arrival 120 , suggesting that communication between primary and secondary sites likely occurs. The site of VEGFR1 + HPC colonization was consistent with the typical metastatic location for each experimental cancer type (LLC and B16 melanoma, in this study), and remarkably, conditioned media from melanoma induced LLC metastasis to atypical sites that recapitulated melanoma metastasis patterns. Depleting VEGFR1 + cells interfered with the formation of these premetastatic clusters and blocked metastasis 120 . In a subsequent study in breast cancer, expression of lysyl oxidase (LOX), a major target of hypoxia-inducible factor (HIF) signaling, facilitated myeloid cell recruitment and subsequent tumor cell colonization hepatocellular carcinoma, CAFs participate in a TGF-b-PDGF signaling crosstalk with tumor cells to support EMT and the acquisition of an invasive phenotype 99 .
The microenvironment at the invasive edge of tumors is quite different than that of the tumor core. Hypoxia tends to be associated with the center of a tumor, whereas oxygen is largely available at the periphery. Given that low oxygen levels are a major driving force for stromal cell behavior and recruitment to tumors [100] [101] [102] , it is intriguing that many stromal cells do not necessarily favor hypoxic regions once they arrive at the tumor site. For instance, in colorectal cancers, although subsets of lymphocytes are present at both the leading edge and the tumor core in primary tumors, these cells have been shown to be predominant at the tumor periphery in liver metastases, where they correlate with response to therapy 57, 103 . In addition, although macrophages have important roles during invasion at the tumor margin, as discussed previously, they have also been shown to thrive in hypoxic conditions in tumors and ischemic tissues and thereby facilitate angiogenesis 37, 38, 104 . The relationship between oxygen and immune cells may inadvertently promote metastatic dissemination in multiple respects: while hypoxia mediates immune cell recruitment, these cells concentrate at the tumor periphery to support cancer invasion at the leading edge. Meanwhile, in the tumor core, hypoxia contributes to cancer cell escape by providing an aggressive selection pressure for resilient stem-like tumor cells that subsequently migrate away to the tumor margin. In light of this complexity, the spatial context of immune cells at the tumor edge as compared to the tumor center may be critical for fully understanding tumor-stroma dynamics.
Dynamic interplay between macrophages and tumor cells during intravasation. Beyond the initial acquisition of invasiveness in primary tumors, the next major rate-limiting step in the metastatic cascade is intravasation into circulation 105 (Fig. 2) . Multiphoton intravital imaging techniques have been used to observe macrophage-tumor interactions during metastatic dissemination in live animals 106, 107 . These approaches have been instrumental in showing that macrophages are localized primarily in the peripheral tumor stroma and decrease in number toward the center. In deep regions of the tumor that are not visible by conventional confocal microscopy, macrophages localize to blood vessels, where they help tumor cells intravasate into the circulation 107 . Moreover, clusters of these three different cell types, termed the tumor microenvironment of metastasis, are also found in human breast cancer, where their increased density correlates with distant metastasis 108 .
Recent studies have indicated that entry into the circulation may not be a late event in tumor progression, as was previously believed [109] [110] [111] . If intravasation indeed requires macrophage-tumor cell interactions with endothelial barriers, it follows that macrophages also have an early role in tumorigenesis. Indeed, in a mouse model of chemically induced lung cancer, resident pulmonary macrophages became activated in response to signals from incipient tumors within days of their onset. However, macrophage numbers in these lesions did not change until months later, indicating that recruitment of BM-derived macrophages is a late event during tumorigenesis 112 . This suggests that if circulating tumor cells are present in early disease, it is possible that this event is mediated by resident, rather than recruited, macrophage populations that are locally activated within the tumor. The kinetics of tumor cell entrance into the bloodstream, and the mechanisms that mediate this putative early event, remain elusive.
Survival in the blood and arrival at secondary organs. Metastasis is a highly inefficient process; only 0.01% of cells that intravasate into circulation are capable of forming detectable metastases 113 . During dissemination, platelets have an important role in the hostile microenvironment of the bloodstream, where they directly interact with tumor cells and enhance survival 94 (Fig. 2) . Platelets in the circulation form protec-'microenvironment mimicry' is an exciting avenue of ongoing research.
Modulating tumorigenesis through exosomes. Many of the examples of heterotypic signaling within the TME discussed here involve classical paracrine signaling loops of cytokines or growth factors and their receptors. Although these signaling mechanisms undoubtedly operate as a key means of intercellular communication within the TME, more recently, exosome shedding has emerged as another mode of cell-cell signaling. In cancer, tumor-derived exosomes from the primary tumor educate their environment to form a pro-tumorigenic niche and direct BM-derived progenitors to enhance and direct metastatic dissemination 15 (Fig. 2) . Exosomes derived from aggressive melanoma cells increased the growth and metastasis of primary tumors and programmed BMDCs at the premetastatic site to assume a proangiogenic phenotype 126 . This effect was dependent on the receptor tyrosine kinase MET, as its inhibition in exosomes impaired pro-metastatic effects. Remarkably, exosomes also altered organ tropism; when exosomes from one melanoma cell line were injected into mice intravenously, they dictated the site of spontaneous metastasis of different subcutaneously implanted melanoma cell lines. Critically, this study identified a prognostic exosome signature, which is detectable in patient blood, that accurately predicts stage and metastatic outcome 126 .
Various stromal cells are also capable of exosome release; for example, fibroblast-secreted exosomes promote breast cancer cell migration through WNT-PCP signaling 127 . NK cell-derived exosomes from human blood contain proteins that induce the cytotoxicity of tumor and activated immune cells ex vivo 128 . Notably, NK cell-derived exosomes are not cytotoxic to resting immune cells, suggesting that their cytolytic effects are directed specifically to activated cells. Exosomes released from DCs, termed dexosomes, are being investigated in clinical trials for their in the lung 123 . LOX inhibition in tumor cells blocked myeloid cell recruitment to premetastatic niches and reduced lung metastasis.
Additional studies have examined whether primary tumor hypoxia influences the premetastatic niche 124 . Specifically, simply injecting mice with conditioned media from breast cancer cells cultured under hypoxic conditions induced infiltration of BM-derived cells (BMDCs) into the lung, despite the absence of an actual primary tumor. Major BMDC contributors to this hypoxia-induced pseudopremetastatic niche included MDSCs and NK cells with impaired cytotoxicity. Collectively, these and other studies 87 demonstrate a critical role for BMDCs in predicting and directing sites of future metastasis and illustrate the importance of systemic communication between primary and secondary organs. It follows that in early stages of disease, patients may benefit from therapeutic intervention that aims to disrupt the premetastatic niche before tumor cells have a chance to arrive.
Another hypothesis regarding organ tropism stems from the observation that primary TMEs can share commonalities with secondary microenvironments. For example, it was recently shown that breast cancer stem cells attempting to colonize secondary sites induce periostin in the resident fibroblasts to recreate the environment of the primary niche 125 . Periostin induction is necessary for colonization and subsequent outgrowth, as it facilitates WNT signaling in tumor cells. Notably, periostin knockout mice exhibited ~90% reduction in lung metastasis, whereas metastasis was unchanged when periostin was specifically inhibited in tumor cells in a wild-type mouse. Similarly, bone metastasis 'seeds' can be selected by mesenchymal-derived factors in the primary breast TME 72 , as discussed above. Whether tropic selection in the primary tumor occurs for other sites of metastasis through this intriguing type of Figure 3 Overcoming tumor dormancy and initiation of secondary outgrowth in metastatic niches. Dormant micrometastases are held in check by several mechanisms. Tumor mass dormancy, or angiogenic dormancy, is when proliferation is balanced by apoptosis because of a lack of vasculature and limited supply of nutrients and oxygen. Multiple cell types contribute to the re-establishment of vascularity at the secondary site, including HPCs and EPCs expressing VEGF receptors and dendritic cell precursors that can differentiate into an endothelial-like state. Tumor cells can also exist in a state of cellular dormancy, whereby proliferation is arrested in G0. This can be overcome by several mechanisms, for example, fibronectin-integrin interactions and activation of EGFR signaling or re-polarization of macrophages from an anti-to a pro-tumorigenic state within the TME. In addition, tumor cells can enter immuneinduced dormancy whereby immunogenic cells are cleared, and cells that are able to survive enter a state of equilibrium. Immune suppressor cells are recruited to tumors in response to this process and contribute to the establishment of an immunosuppressive state within secondary tissues. T reg cells and MDSCs are depicted here, which produce anti-inflammatory cytokines and suppress the anti-tumorigenic capacities of other immune cell types. Once micrometastases overcome dormancy, they become receptive to signals and cell types within their microenvironment to further support their expansion. For instance, TAMs are abundant in metastases of multiple cancer types and support different tumorigenic processes to allow for outgrowth, including vascularization, impaired immunogenicity and enhanced survival in overt metastases. Platelets, and components of the coagulation system such as TF are also important mediators of metastatic outgrowth, as they interfere with the ability of NK cells to destroy micrometastases and support clot formation, which in turn causes the recruitment of MDSCs.
Debbie Maizels been suggested that VEGFR1 + HPCs and VEGFR2 + EPCs are dually required for mediating neovascularization of tumors 141 . This requires inhibitor of DNA binding 1 (Id1) and Id3, as Id1 +/-Id3 -/-mice exhibited angiogenic defects concomitant with impaired tumor growth, and BM transplantation from wild-type donors restored these effects 141 . More recently, MMTV-PyMT mice were reconstituted with GFP + BM and their pulmonary metastases were analyzed, which demonstrated that micrometastases were avascular, whereas macrometastases exhibited angiogenesis with GFP + EPC incorporation 140 . Notably, Id1 inhibition prevented the transition from micrometastatic to macrometastatic growth by blocking EPC recruitment and angiogenic switching 140 .
Another study reported that recruited CD11c + DC precursors assembled into tumor-associated neovessels in an ovarian carcinoma model 139 . Interestingly, these cells contributed to vascularization through a phenotypic transition toward a more endothelial cell-like state 139 . Although these and many other studies document roles for EPCs and BMDCs in promoting tumor-associated angiogenesis and establishing the premetastatic niche, it should be noted that other reports have come to different conclusions 142, 143 , and therefore this remains an active area of discussion in the TME field 144 . Mechanisms of cellular dormancy by cell cycle arrest. Studies in breast cancer found that dormant cells exist in a nonproliferative state in the BM of ~36-56% of patients 145, 146 , irrespective of lymph node status, and detection of these cells is predictive of metastasis and worse survival. Analyses of micrometastases in mouse models demonstrated that these lesions are often completely negative for proliferation markers, suggesting they are in a state of G0-G1 arrest 147 . This arrest is mediated by microenvironment-mediated signals (Fig. 3) , such as integrin interactions through the ECM or deregulated mitogenic or stress signals, and is not necessarily dictated by insufficient vascularization. For example, uPAR (also called PLAUR) can induce EGFR in a ligand-independent manner to promote tumor cell proliferation through fibronectin-α v β I integrin and mitogen-activated protein kinase 1 (ERK, also called MAPK1) activation. Accordingly, uPAR downregulation results in tumor dormancy 134, 148, 149 . Recently it was shown that senescent p53-positive stellate cells in the liver secrete a cocktail of cytokines that cause macrophages to become M2 polarized. This subsequently promotes the proliferation of premalignant hepatocellular carcinoma cells, whereas disruption of p53-induced senescence blocks this progression 150 .
potential as a cancer vaccine 129, 130 . This concept is supported by preclinical melanoma models in which dexosome immunization induced CD8 + cytotoxic T cells and delayed tumor growth 131 .
Overcoming tumor dormancy and metastatic outgrowth Even if tumor cells successfully seed secondary organs, this does not ensure their survival or expansion. The microenvironment at the secondary site can actively suppress metastatic cell survival and outgrowth, for example, by neutrophil-mediated killing of tumor cells 132 or thrombospondin-1 secretion by BM-derived Gr1 + cells 133 . Alternatively, as we discuss in the next section, tumor cells can survive initial cell-clearing defense mechanisms in secondary organs and subsequently exist as asymptomatic dormant micrometastases that can persist in the body for years without detection. Tumor dormancy is mediated by several processes that are driven in part by the microenvironment (Fig. 3) , including tumor mass dormancy (proliferation is balanced by apoptosis), cellular dormancy (cells are arrested in G0) or immune dormancy (immunoediting leads to a state of equilibrium) [134] [135] [136] .
Flipping the angiogenic switch at the secondary site. One major limiting step of metastasis is outgrowth in secondary locations, which is dependent in part on establishing a blood supply, as in the primary TME. An inability of tumors to grow beyond a certain size because of insufficient vascularization is termed angiogenic or tumor mass dormancy 134 . At secondary sites, angiogenic dormancy is characterized by avascular micrometastatic lesions that do not grow beyond 1-2 mm in diameter (in accordance with the diffusion limit of oxygen 137 ) because of a balance between proliferation and apoptosis. The angiogenic switch marks the transition out of this dormant state, at which point metastases are said to be 'macro' (i.e., larger than 1-2 mm because of vascular infiltration) and exhibit elevated proliferation rates compared to apoptosis 134, 137 . That tumor growth is dependent on the ability to recruit a vasculature has been reported extensively in multiple tumor types and is closely linked to the composition of the tumor-associated stroma 5 . Supporting this concept, a recent study elegantly demonstrated that a dormant niche was associated with mature vessels and endothelial-derived thrombospondin-1, whereas metastatic outgrowth was associated with sprouting neovessels and production of periostin and TGF-β 138 .
Several studies have demonstrated critical roles for recruited BMDCs in overcoming angiogenic dormancy (Fig. 3) [139] [140] [141] . For instance, it has BOX 2 Mechanisms of resistance in response to TME-targeted therapies Although some successful TME-targeted therapies currently exist, specific depletion of one stromal cell type within tumors can lead to a state of imbalance within the TME, thereby leading to alterations in other stromal cell populations that contribute to intrinsic or acquired resistance. Moreover, some TME-targeted therapies, such as ipilimumab, only work in a subset of patients, and uncovering the mechanisms of therapeutic resistance in nonresponders is currently a high priority. Ipilimumab depends strongly on T cell infiltration in responding patients, whereas patients that do not respond to therapy lack this infiltration response and present with an abundance of tumor-associated immunosuppressive cell types. As one example, indoleamine 2,3-dioxygenase (IDO) derived from tumor cells, macrophages and DCs was identified as a major contributor to an immunosuppressed state, as defined by reduced numbers of CD8 + T cells and high numbers of T reg cells 196 . In mouse models, dual targeting of CTLA-4 and IDO caused rejection of established melanoma and breast tumors, mediated by reduced numbers of T reg cells and increased numbers of CD8 + T cells. This effect extends to other T cell-targeted strategies, including antibodies to PD1 or glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR, a T cell inducer that mediates tumor immunity). Dual targeting of PD1 or GITR and IDO causes a greater reduction in tumor growth compared to either therapy alone, suggesting that IDO mediates resistance to multiple immune checkpoint therapies and that its effects are not limited to ipilimumab. In another example of how the TME can be subverted to interfere with T cell therapy, it was shown that melanomas acquire resistance through inflammation-induced loss of melanocytic antigens, leading to dedifferentiation through a TNF-a-mediated mechanism 197 . Finally, several groups have demonstrated TME alterations after traditional anticancer therapies, for example, TAM accumulation 35, 176, 198 , which severely impair therapeutic efficacy. Together these and other recent studies underscore how the microenvironment can subvert therapeutic efficacy and ultimately abrogate patient outcome, emphasizing the necessity of investigating the global TME response in all aspects of therapeutic targeting in future studies. petent mice, owing largely to the differences in immune selection pressures within each type of host 152 .
Tumor cell variants that are able to survive immunosurveillance enter a state of dynamic equilibrium, which is a form of immune-mediated tumor dormancy that prevents the outgrowth of remaining tumor cells 135, 153 . This tumor-immune equilibrium is driven by a strong selective pressure from the adaptive arm of the immune system, including T cells and T H 1 cytokines (for example, interferon-g (IFN-g) or IL-12) and does not require the recognition of effector cells (Fig. 3) 153 . Evidence for this mechanism came from observations that carcinogen-induced tumors frequently remain dormant and asymptomatic in immunocompetent mice; however, when mice are treated with antibodies to T cells and IFN-g, tumors grow at the site of induction 153 . Clinically, it is known that tumors can remain dormant and asymptomatic in patients for years or even decades before relapsing and that patients who appear to be in full remission still have tumor cells circulating in their blood. Although it is unlikely that these phenomena are dictated solely by immune pressures, these observations are provoking; perhaps directing the immunoediting process to remain in the equilibrium phase could synergize with standard-of-care therapy to manage incurable disease and maximize the remission period for patients.
Tumor awakening and metastatic outgrowth. Immunoedited tumors are at risk of exiting their equilibrium (Fig. 3) . Given that tumor Additional insight into the role of secreted factors in helping maintain, and subsequently overcome, dormancy came from a recent screen in metastatic breast cancer 151 . Bone morphogenic protein (BMP) signaling suppressed tumor stem cell traits, whereas COCO (also called DAND5), a secreted BMP antagonist, reactivated tumor cells, leading to metastatic outgrowth. Interestingly, these signals were operational only in the lung and not in the brain or bone 151 , indicating that metastasis-initiating cells may override microenvironment-mediated suppression in an organspecific manner.
Immune-induced tumor dormancy. The notion that tumor cells can be recognized and destroyed by the immune system was first proposed by Burnet and Thomas in the 1950s. This theory was met with great controversy in the field, as early experiments were not successful in supporting their hypothesis. However, we now know that tumor cells are indeed recognized and destroyed through immunosurveillance, which molds the tumor and selects for less immunogenic cells 135 . This process, termed immunoediting, parallels Darwinian selection, whereby tumor cells that are vulnerable to attack by the immune system are cleared, whereas cells that have or acquire a capacity to circumvent surveillance can survive and propagate a new tumor that is primed to evade the immune system. The concept of immunoediting is supported by the finding that tumors derived from immunodeficient mice are more immunogenic than tumors derived from immunocom- . Repolarization or re-education of cells within the TME, in particular, macrophages or other myeloid cells, can be achieved by CSF-1R inhibition (for example, BLZ945) or monoclonal antibodies that activate CD40. Alternatively, immune cell recruitment and expansion can be blocked through inhibition of critical cytokine axes, such as CXCR4 (AMD3100), CXCR2 (S-265610), CSF-1R and/or KIT (PLX3397), and the chemotherapeutic agent trabectedin, whose anti-tumor activity is proposed to be a result of selective depletion of monocytes and/or macrophages 177 . Likewise, metastatic seeding and outgrowth can be blocked by inhibition of key cytokine axes, such as CCR2 (MLN1202).
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to both promote and impair tumor growth, an avenue of therapeutic intervention worth exploring may be to harness this inherent plasticity by developing strategies to manipulate and re-educate the TME rather than to simply target TME components for depletion or destruction.
Immunotherapies that are currently generating much excitement in the clinic 11, 155, 167, 168 are a classic example of such a reprogramming approach.
Various therapies attempt to block mechanisms of immune evasion by tumors, many of which are currently focused on patients with advanced melanoma, given their high numbers of lymphocytes 167 . Ipilimumab is a US Food and Drug Administration-approved antibody that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which activates T cells and promotes anti-tumor immunity 167 . In the first clinical trial for ipilimumab in patients with inoperable metastatic melanoma, overall survival increased to ~10 months as compared to 6.4 months for those patients not on ipilimumab therapy 169, 170 . Several drugs have been combined with ipilimumab to further improve patient outcome. For example, nivolumab, an antibody targeting the programmed death 1 (PD1) receptor, was used in combination or in sequence with ipilimumab to treat patients with advanced melanoma. PD1 represses T cell effector function and limits the immune response to tumors, thus enabling immune evasion. Results from this phase 1 trial revealed that patients receiving a maximum-dose combination regimen exhibited >80% tumor volume reduction 171 . Similarly, lambrolizumab, a blocking antibody to PD1 ligand (PD-L1), was used in patients with metastatic melanoma who had either been treated previously with ipilimumab or not 172 . In the optimal dosing group, the response rate was 52%, and overall progression-free survival was >7 months 172 . Another immunotherapy success story involves a different approach using agonistic antibodies to activate CD40, a TNF receptor superfamily member that is broadly expressed on immune cells. The CD40 monoclonal antibody reverses immune suppression by collectively activating antigen-presenting cells, promoting antitumor T cell responses and re-educating cytotoxic myeloid cells 173 . Interestingly, preclinical pancreatic cancer studies demonstrated that the combined efficacy of the CD40 monoclonal antibody and gemcitabine required macrophage activation 174 . Taken together, these studies suggest that combining therapies targeting tumor mechanisms of immune evasion (for example, removing suppressive cell types through neutralization of PD1 or PD-L1) with activation of normal immune cell functionality (i.e., T cell activation) may provide optimal benefits for patients; however, these trials are still in the early stages, and our mechanistic understanding of how these drugs contribute to efficacy and overall survival remains incomplete. Moreover, the long-term impact of these therapies on patient safety and survival will take several years to fully evaluate.
Further emerging examples of TME-directed therapies that do not focus on target cell depletion include the concept of neutralizing tumorassociated chronic inflammation 175 . Among the cell types and signaling molecules we discussed here, strategies that block the NF-kB pathway or inhibition of key cytokine pathways that dictate recruitment and/or immune cell function, for example, through CSF-1R, CCR2 or CXCR2, among others, are being investigated in clinical trials (Fig. 4) that are based in part on preclinical successes 25, 158, 176 . For example, in a recent study, a CSF-1R inhibitor was used to target macrophages and microglia in the TME of gliomas 25 . This resulted in a robust decrease in tumor volume concomitant with a significant prolongation in survival in preclinical trials and reprogramming rather than depletion of macrophages 25 . In contrast, CSF-1R inhibitors deplete TAMs in preclinical models of breast cancer, yet this has no effect on primary tumor growth unless these inhibitors are used in combination with other therapies 176 . Given that cells are inherently genetically unstable, the strong immune pressure placed on tumor cells in equilibrium makes them susceptible to acquiring mutations that may allow for immune evasion and outgrowth. These adapted tumors frequently exhibit defects in antigen presentation, processing or both, for example, through loss of MHC class I or latent membrane protein (LMP)-family molecules 154 , rendering them undetectable by the adaptive immune system. They are also capable of establishing a global immunosuppressive state in the TME by secreting a plethora of anti-inflammatory cytokines, including TGF-b and VEGF, or by recruiting immunosuppressive cell types, including T reg cells and MDSCs, which further contribute to the anti-inflammatory cytokine milieu, as described earlier. Indeed, immune therapies are being used increasingly in patients with cancer, aiming to curtail aberrant immune responses to growing tumors 155 .
Besides escaping immunosurveillance, tumors are similarly prone to exiting angiogenic-mediated or cell cycle-mediated mechanisms of dormancy, enabling the development of lethal macrometastases. Several factors contribute to this process in addition to immune suppression, including sustained vascularization and enhanced survival. One cell type that is important for all of these processes is recruited TAMs. In patients with pancreatic cancer, peripheral M2-polarized macrophages are associated with the establishment and growth of liver metastases 156 . Similarly, in breast cancer models, TAMs mediate extravasation and metastatic outgrowth of tumor cells in the lung, and blocking TAMs with clodronate liposomes or through genetic ablation of CSF1 significantly interfered with both processes 157 . More recently, a new population of metastasis-associated macrophages was identified, which promoted the extravasation, seeding and outgrowth of breast cancer cells in the lung 158 . Interestingly, inhibition of CCL2-CCR2 signaling specifically prevented metastasis-associated macrophage accumulation and reduced metastasis in mice 158 . In a comparison of tumor-associated lymphomonocytes in patients with cancer as compared to autologous peripheral blood mononuclear cells, it was found that tumor-associated lymphomonocytes were associated with impaired immunogenic function and secreted elevated levels of cytokines that are reported to enhance tumor growth 159 . Together these studies illustrate the multifaceted functions of immune cells in advanced disease stages.
Interestingly, a role for the coagulation system has been demonstrated not only in circulation but also during metastatic outgrowth. One coagulation protein in particular, tissue factor (TF), correlates with poor prognosis in patients, as it interferes with NK cell-mediated lysis of micrometastases 160, 161 . TF inhibition with recombinant tissue factor pathway inhibitor or TF-targeted shRNAs in mouse melanomas blocked lung metastasis 162 . Furthermore, TF induced platelet clots, leading to BM-derived macrophage recruitment to support melanoma survival in the lung 160 . These clots also recruited MDSCs to secondary lesions, thereby suppressing immune rejection of the tumor 160 . That tumors use the coagulation system to support disease progression is yet another example of normal tissue homeostasis being hijacked in cancer.
Therapeutic strategies for re-educating the TME Most therapeutic strategies against cancer have focused on targeting various aspects of tumor cells directly; however, stromal cells within the TME are genetically stable compared to tumor cells and are thus likely to be less susceptible to classical mechanisms of therapeutic resistance. Moreover, given the accumulating evidence of overwhelming heterogeneity at every level in cancer cells 163, 164 , targeting the TME becomes an even more compelling option (Fig. 4) 165 . Therapies aiming to deplete stromal cells, including various angiogenesis inhibitors 166 , have had limited benefits, possibly because they generally block the pro-tumorigenic effects of the TME. Given the paradoxical capacity of the TME breast and brain cancers respond very differently to CSF-1R inhibition in their primary environments, whether a similar treatment modality would work for brain metastases from a breast primary tumor would be interesting to investigate, as these treatments target the microenvironment specifically. It is plausible that TME-targeted therapies should be administered to patients depending on where their tumor is located, in addition to what type of tumor they have, and that dual targeting of tumor cells and their local environment may have robust consequences for mitigating metastasis.
Conclusions
This is an exciting time for the TME field, as illustrated by the examples discussed here, which have revealed new biological concepts and identified new therapeutic strategies to target the TME. Nonetheless, with these advances come new challenges, the most obvious of which is how to identify and target susceptible nodes in the increasingly complex and interconnected TME (Fig. 4) . Indeed, given that TMEs and key signaling pathways are broadly diverse between different tumor types and tissues, insights into how to manage this diversity and how different TMEs may alter response to current standard-of-care therapies will be important areas to investigate going forward. Another largely unexplored question in the field is how the TME may be educated and sculpted by specific oncogenic driver(s) in the tumor cells and how this could result in stromal cell diversity-even within the same tissue. Additional points to consider include determining which patients to target, which anticancer therapies to combine with TME-targeted agents and how to overcome intrinsic or acquired resistance in the TME (Box 2). However, from the studies highlighted in this Review, we now have a roadmap to convert these challenges into opportunities. For example, patient selection will require analysis of the entire TME 57, 176 , not simply individual cell types in isolation, to determine specific therapies to use. Tumor cell-directed agents will also need to be combined with TME therapies in a manner that considers how stromal cells modulate the efficacy of a broad range of standard chemotherapies and targeted agents. Looking forward, perhaps the greatest promise may come from the notion that re-educating a dysfunctional TME could yield striking results in cancer control and remission, as evidenced by the accumulating success stories in the cancer immunotherapy field.
